File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer

TitleLongitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer
Authors
KeywordsLung cancer
circulating tumor DNA (ctDNA)
epidermal growth factor receptor (EGFR)
longitudinal assessment
tumor burden
Issue Date2020
PublisherAME Publishing Company. The Journal's web site is located at http://www.tlcr.org/
Citation
Translational Lung Cancer Research, 2020, v. 9 n. 5, p. 1873-1884 How to Cite?
AbstractBackground: Most studies associating circulating tumor DNA (ctDNA) with outcome in lung cancer treatment were either cross-sectional or, if longitudinal, only analyzed a limited number of genes. This study evaluated the potential of utilizing ctDNA profiled by a panel of common cancer genes to monitor tumor burden and to reveal molecular characteristics of tumor along treatment course. Methods: Twenty Chinese non-small cell lung cancer (NSCLC) patients with serial plasma samples collected (I) before starting on either first- or second-line treatment, (II) at stable disease on treatment, and (III) upon disease progression, were analyzed for mutations in ctDNA using the PGDx 64-gene panel. Paired statistics compared mutation profiles between any two of the three time points. Results: Proportions with detectable ctDNA decreased from 65% at baseline to 35% at stable disease and rose to 80% at progression (P=0.012, between stable disease and progression); median ctDNA levels (mutated fragments per mL) were 7.8, 0, and 24.7 at the three time points, respectively (P=0.013 between baseline and progression; P=0.007 between stable disease and progression). Although plasma epidermal growth factor receptor (EGFR) mutations were commonly detected, 15% of patients had mutations other than EGFR detected during progression, such as various types of TP53 mutations. Conclusions: ctDNA profiling in serial blood samples reflected tumor burden over time, and a multi-gene panel was more sensitive in indicating lung cancer progression on treatment than a single gene approach. The detection of additional oncogenic mutations or their disappearance suggested evolution of tumor heterogeneity along treatment course.
Persistent Identifierhttp://hdl.handle.net/10722/304700
ISSN
2023 Impact Factor: 4.0
2023 SCImago Journal Rankings: 1.318
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHo, GYF-
dc.contributor.authorWang, T-
dc.contributor.authorKwok, HH-
dc.contributor.authorRasul, R-
dc.contributor.authorPeila, R-
dc.contributor.authorGuzman, M-
dc.contributor.authorIp, MSM-
dc.contributor.authorLam, CLD-
dc.date.accessioned2021-10-05T02:33:53Z-
dc.date.available2021-10-05T02:33:53Z-
dc.date.issued2020-
dc.identifier.citationTranslational Lung Cancer Research, 2020, v. 9 n. 5, p. 1873-1884-
dc.identifier.issn2218-6751-
dc.identifier.urihttp://hdl.handle.net/10722/304700-
dc.description.abstractBackground: Most studies associating circulating tumor DNA (ctDNA) with outcome in lung cancer treatment were either cross-sectional or, if longitudinal, only analyzed a limited number of genes. This study evaluated the potential of utilizing ctDNA profiled by a panel of common cancer genes to monitor tumor burden and to reveal molecular characteristics of tumor along treatment course. Methods: Twenty Chinese non-small cell lung cancer (NSCLC) patients with serial plasma samples collected (I) before starting on either first- or second-line treatment, (II) at stable disease on treatment, and (III) upon disease progression, were analyzed for mutations in ctDNA using the PGDx 64-gene panel. Paired statistics compared mutation profiles between any two of the three time points. Results: Proportions with detectable ctDNA decreased from 65% at baseline to 35% at stable disease and rose to 80% at progression (P=0.012, between stable disease and progression); median ctDNA levels (mutated fragments per mL) were 7.8, 0, and 24.7 at the three time points, respectively (P=0.013 between baseline and progression; P=0.007 between stable disease and progression). Although plasma epidermal growth factor receptor (EGFR) mutations were commonly detected, 15% of patients had mutations other than EGFR detected during progression, such as various types of TP53 mutations. Conclusions: ctDNA profiling in serial blood samples reflected tumor burden over time, and a multi-gene panel was more sensitive in indicating lung cancer progression on treatment than a single gene approach. The detection of additional oncogenic mutations or their disappearance suggested evolution of tumor heterogeneity along treatment course.-
dc.languageeng-
dc.publisherAME Publishing Company. The Journal's web site is located at http://www.tlcr.org/-
dc.relation.ispartofTranslational Lung Cancer Research-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectLung cancer-
dc.subjectcirculating tumor DNA (ctDNA)-
dc.subjectepidermal growth factor receptor (EGFR)-
dc.subjectlongitudinal assessment-
dc.subjecttumor burden-
dc.titleLongitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer-
dc.typeArticle-
dc.identifier.emailKwok, HH: kwokh@hku.hk-
dc.identifier.emailIp, MSM: msmip@hku.hk-
dc.identifier.emailLam, CLD: dcllam@hku.hk-
dc.identifier.authorityIp, MSM=rp00347-
dc.identifier.authorityLam, CLD=rp01345-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.21037/tlcr-20-675-
dc.identifier.pmid33209609-
dc.identifier.pmcidPMC7653134-
dc.identifier.scopuseid_2-s2.0-85096121221-
dc.identifier.hkuros326332-
dc.identifier.volume9-
dc.identifier.issue5-
dc.identifier.spage1873-
dc.identifier.epage1884-
dc.identifier.isiWOS:000582799700019-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats